Skip to main content

Table 5 Hospitalization days in different treatment groups or in patients with or without Arbidol based on gender, age and maximum body temperature

From: Clinical features and efficacy of antiviral drug, Arbidol in 220 nonemergency COVID‐19 patients from East-West-Lake Shelter Hospital in Wuhan: a retrospective case series

Feature Without Arbidol (n = 49) With Arbidol (n = 72) p value OR (95% CI)
Hospital day [M (IQR)] 18 (16, 20) 17 (14, 21) 0.25  
  Control (n = 21) Other antiviral drugs (n = 28) Arbidol only (n = 48) Arbidol + other antiviral drugs (n = 24)
Hospital day [M (IQR)] 19 (17, 21) 18 (14, 20) 15.5 (12, 20) *a 19.5 (17, 21)
Male Without Arbidol (n = 24) With Arbidol (n = 40) p value
Hospital day [M (IQR)] 19 (14.5, 20) 16 (14, 20) 0.25
Female Without Arbidol (n = 25) With Arbidol (n = 32) p value
Hospital day [M (IQR)] 18 (16.5, 20) 18 (13.3, 21) 0.75
≤ 50 years Without Arbidol (n = 23) With Arbidol (n = 49) p value
Hospital day [M (IQR)] 18 (17, 20) 17 (13.5, 20.5) 0.04*
> 50 years Without Arbidol (n = 26) With Arbidol (n = 23) p value
Hospital day [M (IQR)] 18 (14, 20) 18 (14, 21) 0.94
 ≤ 38.5C Without Arbidol (n = 33) With Arbidol (n = 51) p value
Hospital day [M (IQR)] 19 (16.5, 20) 18 (14, 21) 0.23
> 38.5C Without Arbidol (n = 16) With Arbidol (n = 21) p value
Hospital day [M (IQR)] 17.5 (14, 19) 17 (12.5, 20) 0.73
  1. *Statistically significant p vaues
  2. aControl group versus Arbidol group (p = 0.02)